相关实验视频
Updated: May 31, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.3K
机器学习和分子动力学模拟预测了2型糖尿病治疗的潜在TGR5激动剂
Ojochenemi A Enejoh1, Chinelo H Okonkwo2, Hector Nortey3
1Genetics, Genomics and Bioinformatics Department, National Biotechnology Research and Development Agency, Abuja, Nigeria.
Frontiers in chemistry
|January 24, 2025
概括
机器学习和模拟确定了Takeda的新型G蛋白结合受体5 (TGR5) 激活剂. 这些化合物通过改善血糖控制,显示出开发更安全,更有效的2型糖尿病治疗的潜力.
科学领域:
- 计算化学和化学信息学
- 药理学和药物发现
- 代谢性疾病研究研究
背景情况:
- 由于复杂的代谢途径,2型糖尿病 (T2D) 的治疗具有挑战性.
- 塔凯达G蛋白结合受体5 (TGR5) 是T2D治疗的有希望的标,调节葡萄糖平衡和能量消耗.
- TGR5激动剂可以改善血糖控制,使它们成为有吸引力的治疗候选者.
研究的目的:
- 确定新型小分子作为T2D治疗的潜在TGR5激动剂.
- 探索机器学习 (ML),分子对接 (MD) 和分子动力学模拟 (MDS) 在药物发现中的实用性.
- 预测和验证具有TGR5.5高亲和度和稳定性的化合物.
主要方法:
- 从ChEMBL数据库中收集已知的TGR5激动剂的生物活性数据.
- 使用分子描述符开发了一个随机森林ML模型,并选了COCONUT数据库.
- 在最高得分的化合物上进行了分子对接和100ns分子动力学模拟.
主要成果:
- 该ML模型预测了来自COCONUT数据库的潜在TGR5激动剂.
- 分子对接表明,化合物对TGR5的亲和力比同结晶的配体更强.
- 分子动力学模拟证实了TGR5活性部位内的化合物的结合稳定性.
结论:
- ML,MD和MDS的综合方法对于发现新型TGR5激动剂是有效的.
- 鉴定到的化合物显示出在T2D治疗策略中优化潜力.
- 这项研究强调了一种强大的计算策略,用于识别代谢疾病的新药候选者.
相关概念视频
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136

